McPeak Merrill A's Form 4 filing
Iovance Biotherapeutics, Inc.IOVA · filed Jun 2, 2022
- Accession no.
- 0001104659-22-067763
- Filed
- Jun 2, 2022
- Trade date
- May 31, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market purchases total $136.4K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| McPeak Merrill ACIK 0001210317 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 31, 2022 | Common Stock | PPurchaseAcquired | +10,000 | $6.84 | +$68,400 | 20,150 | Direct | |
| May 31, 2022 | Common Stock | PPurchaseAcquired | +10,000 | $6.80 | +$68,000 | 218,633 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.